Ke Wang
Pfizer
7 Papers
Ke Wang is an academic researcher from Pfizer. The author has contributed to research in topics: Engineering & Catalysis. The author has an hindex of 6, co-authored 7 publications.
Chat about Author
Papers
The Evolution of High-Throughput Experimentation in Pharmaceutical Development and Perspectives on the Future
Steven M. Mennen,Carolina Alhambra,C. Liana Allen,Mario Barberis,Simon Berritt,Thomas Andrew Brandt,Andrew D. Campbell,Jesús Castañón,Alan H. Cherney,Melodie Christensen,David B. Damon,J. Eugenio de Diego,Susana García-Cerrada,Pablo Garcia-Losada,Rubén Haro,Jacob M. Janey,David C. Leitch,Ling Li,Fangfang Liu,Paul C. Lobben,David W. C. MacMillan,Javier Magano,Emma McInturff,Sebastien Monfette,Ronald J. Post,Danielle M. Schultz,Barbara J. Sitter,Jason M. Stevens,Iulia I. Strambeanu,Jack Twilton,Ke Wang,Matthew A. Zajac +31 more
TL;DR: This review will deliver an overview of the latest best practices currently taking place within teams in process chemistry by sharing frequently studied transformations, the perspective for the next several years in the field, and manual and automated tools to enable experimentation.
404
Palbociclib Commercial Manufacturing Process Development. Part I: Control of Regioselectivity in a Grignard-Mediated SNAr Coupling
Shengquan Duan,David Place,Hahdi H. Perfect,Nathan D. Ide,Mark T. Maloney,Karen Sutherland,Wiglesworth Kristin,Ke Wang,Mark Olivier,Fangming Kong,Kyle R. Leeman,Jon Blunt,John Draper,Marie McAuliffe,Maria M. O’Sullivan,Denis Lynch +15 more
TL;DR: In this paper, the SNAr coupling between aminopyridine 3 and chloropyrimidine 7 was studied from a synthetic and mechanistic perspective, and Grignard bases were identified as the preferred class of bases for this reaction.
44
Deprotection of N-Boc Groups under Continuous-Flow High-Temperature Conditions.
Bryan Li,Ruizhi Li,Dorff Peter H,J. Christopher McWilliams,Robert M. Guinn,Steven M. Guinness,Lu Han,Ke Wang,Shu Yu +8 more
TL;DR: The scope of thermolytic, N-Boc deprotection was studied on 26 compounds from the Pfizer compound library, representing a diverse set of structural moieties, and a strong correlation was found to exist between the electrophilicity of the N- Boc carbonyl group and the reaction rate.
37
Control of Mutagenic Impurities: Survey of Pharmaceutical Company Practices and a Proposed Framework for Industry Alignment
Christopher J. Borths,Mark D. Argentine,John Donaubauer,Eric L. Elliott,Jared Evans,Timothy T. Kramer,Heewon Lee,Rodney L. Parsons,Jeffrey C. Roberts,Gregory W. Sluggett,Andrew Teasdale,Michael Urquhart,Ke Wang,Ping Zhuang +13 more
TL;DR: The ICH M7 provides several risk-based control options to manage mutagenic impurities (MI and PMIs) in the manufacture of pharmaceuticals as mentioned in this paper. But these control options are not risk-sensitive.
13
Palbociclib Commercial Manufacturing Process Development. Part II: Regioselective Heck Coupling with Polymorph Control for Processability
Mark T. Maloney,Brian P. Jones,Mark Olivier,Javier Magano,Ke Wang,Nathan D. Ide,Andrew S. Palm,David R. Bill,Kyle R. Leeman,Karen Sutherland,John Draper,Adrian M. Daly,Joseph Keane,Denis Lynch,Marie O’Brien,Joanne Tuohy +15 more
TL;DR: A three-step commercial manufacturing route has been developed for palbociclib, a highly selective, reversible inhibitor of CDK 4/6 as mentioned in this paper, which utilizes a Heck coupling to install the enol ether side chain.